National immunization plan newly adjusts two types of vaccine immunization procedures
Release date: 2020-01-03 Views: 0
Recently, the State Health and Medical Commission, the Ministry of Finance, the Ministry of Industry and Information Technology and the State Drug Administration jointly issued the "Notice on the Work Related to the Adjustment of the Immunization Program for Polio Vaccines and Measles-containing Vaccines of the National Immunization Program" (hereinafter referred to as the notice). Since December 2019, the immunization program for polio vaccine has been adjusted from the original 1 dose of IPV injection + 3 doses of bOPV oral drops to 2 doses of IPV injection + 2 doses of polio bOPV oral drops.
At the same time, starting from June 2020, two immunization programs of the combined measles-mumps-rubella live attenuated vaccine (triple vaccine for measles and mumps) will be implemented nationwide, once each at 8 months and 18 months. The previous immunization program was one dose of leprosy vaccine at 8 months of age and one dose of leprosy vaccine at 18-24 months of age.
In addition, the "Notice" also proposes that all waste health, finance, industry and information technology, drug supervision and other departments under the leadership of the local Meifu should establish a clear and responsible department coordination mechanism to fully ensure the smooth adjustment of immunization procedures. get on. The health department is responsible for formulating the implementation plan and annual plan for the adjustment of the immunization program for polio vaccine and measles-containing vaccines of the national immunization plan, and organizing the implementation; the financial department is responsible for implementing the national immunization plan for polio vaccine, measles layer adenitis and rubella Expenditures for the purchase of combined live attenuated vaccines and syringes and for the need for immunization work; industry and information technology departments are responsible for urging enterprises to implement the national immunization plan polio vaccine and measles component vaccine production plan, and drug regulatory agencies are responsible for the national immunization program spinal cord Approval for marketing of polio vaccine and measles component vaccines and quality supervision of production and distribution. All relevant departments need to seize co-management and cooperate closely to form a seamless connection and jointly implement various measures.
According to China's current laws and regulations, vaccines are divided into two categories. The first type of vaccine refers to vaccines provided by the government to citizens free of charge. Citizens should be vaccinated in accordance with government regulations, including vaccines determined by the national immunization plan, and vaccines added by the people's governments of provinces, autonomous regions, and municipalities directly under the national immunization plan. Vaccines used for emergency vaccination or mass vaccination organized by people's governments at or above the county level or their health authorities; the second type of vaccine refers to other vaccines that are self-funded and voluntarily received by citizens.
Among them, the national immunization plan vaccine refers to the planned vaccine formulated according to the national infectious disease prevention and control plan and the use of effective vaccines for vaccination of susceptible people. China has fully implemented planned immunization since 1978. The national immunization plan vaccine has been expanded from 4 to 14 (including Hepatitis A, Hepatitis B, Poliomyelitis, Mump, JE, etc.), and preventable infectious diseases have expanded from 6 According to the actual situation, the country has dynamically adjusted immunization plans in recent years. For example, in May 2016, a new polio vaccine immunization policy was implemented, the trivalent polio attenuated vaccine (tOPV) was discontinued, and the bivalent spine was used. Replacement of gray attenuated vaccines and integration of polio-inactivated vaccines into national immunization programmes.
In January 2017, the State Council issued the "Thirteenth Five-Year Plan of Health and Health Planning", which proposed to expand the national immunization plan, adjust the national immunization plan vaccine types in a timely manner according to the needs of disease prevention, and gradually incorporate safe, effective, and financially affordable vaccines into the country. Immunization planning.
Changes in the national immunization plan will also bring changes in the market. According to public information, current domestic suppliers of IPV vaccines include Sanofi, the Institute of Medical Biology of the Chinese Academy of Medical Sciences, and Beijing Beishengyan Biological, a subsidiary of China Biotechnology Co., Ltd. Products Co., Ltd. three. In addition, according to the Financial Associated Press, several other companies, including Tiantan Biological and Kangtai Biological's wholly-owned subsidiaries, Minhai Biological, are promoting their IPV projects. Among them, Kexing Biological and China Biological Wuhan Company (Wuhan Biological Products Research Institute) have submitted applications for the listing of IPV vaccines in January and February 2019, respectively.
Judging from the adjustment of the immunization program of measles-containing vaccines, the demand for measles vaccine will increase, while the demand for leprosy vaccine will decrease. Judging from the 2019 batch of vaccines issued, the 2019 leprosy vaccine is only issued by the Shanghai Biological Products Research Institute (Shanghai Institute) of China Biological, and the leprosy vaccine mainly involves Minhai Biological and Beishengyan Biological Products Co., Ltd.
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda Medical (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Introduction of Bermoudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- 1月2日国家卫健委发布今年第一份文件 1. The National Health Commission issued the first document of the year on January 2
- 国家免疫规划最新调整两类疫苗免疫程序 2. National immunization plan recently adjusted two types of vaccine immunization procedures
- 盘点| 2020年将在美欧获得监管批准的10个抗体药物 3. Inventory | 10 antibody drugs that will receive regulatory approval in the US and Europe in 2020
- 2020年生物制药行业最快增长从哪来？ 4. Where will the fastest growth of the biopharmaceutical industry come in 2020? AZ, Merck who is the biggest winner?
- 新一轮国家集采细则来了 5. A new round of national collection and procurement rules has arrived
- 重大政策落地影响所有药企 6. The implementation of major policies affects all pharmaceutical companies
- 2019年终盘点：基因工程领域解读 7. End of 2019 inventory: interpretation of the field of genetic engineering